Fair Value Measurements [Abstract]
Fair Value Measurements [Abstract]
Fair Value Disclosures
Fair Value Disclosures [Text Block]
Income Statement [Abstract]
Statement [Table]
Statement [Table]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Statement [Line Items]
Statement [Line Items]
Revenues
Revenues [Abstract]
Research and development
Research and Development Revenue
Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.
Operating expenses
Operating Expenses [Abstract]
Selling, general and administrative
Selling, General and Administrative Expense
Research and development
Research and Development Expense
Patent preparation fees
Patent Preparation Fees
The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.
Litigation accrual
Loss Contingency, Loss in Period
Total operating expenses
Operating Expenses
Operating loss
Operating Income (Loss)
Decrease (increase) in fair value of common stock warrants
Fair Value Adjustment of Warrants
Non-cash interest expense
Interest Expense
Other income, net
Nonoperating Income (Expense)
Reorganization items, net
Reorganization Items
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Benefit from (provision for) income taxes
Income Tax Expense (Benefit)
Net and comprehensive income (loss)
Net Income (Loss) Attributable to Parent
Earnings (loss) per share: basic and diluted
Earnings Per Share, Basic and Diluted
Weighted average shares outstanding: basic and diluted
Weighted Average Number of Shares Outstanding, Basic and Diluted
Property, Plant and Equipment [Abstract]
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Subsequent Events [Abstract]
Subsequent Events [Text Block]
Subsequent Events [Text Block]
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Stock Option [Member]
Employee Stock Option [Member]
Stock Appreciation Rights (SARs) [Member]
Stock Appreciation Rights (SARs) [Member]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Warrants [Member]
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Restricted Stock Units
Restricted Stock Units
Restricted Stock Units have been vested but not converted into common stock
Weighted average
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]
Financial Instruments Disclosure [Text Block]
Research and Development [Abstract]
Procurement Contract and Research Agreements
Procurement Contract and Research Agreements [Text Block]
The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.
Balance Sheet Parenthetical [Abstract]
Balance Sheet Parenthetical [Abstract]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Common Stock, Shares Authorized
Common Stock, Shares Authorized
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Reorganization [Abstract]
Reorganization [Abstract]
Reorganization, Legal fees
Debtor Reorganization Items, Legal and Advisory Professional Fees
Reorganization, Professional fees
Reorganization, Professional Fees
Amount of reorganization items related to professional fees related to entities in bankruptcy.
Reorganization, Trustee fees
Reorganization, Trustee fees
Amount of reorganization items for trustee fees related to entities in bankruptcy.
Reorganization, Other expense
Debtor Reorganization Items, Other Expense (Income)
Reorganization Items
Reorganization payments
Reorganization Payments
The amount the Company paid for reorganization items.
Statement of Financial Position [Abstract]
ASSETS
Assets [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Restricted cash
Restricted Cash and Investments, Current
Accounts receivable
Accounts Receivable, Net, Current
Inventory
Inventory, Net
Prepaid expense and other assets, current
Prepaid Expense and Other Assets, Current
Deferred tax assets
Deferred Tax Assets, Net of Valuation Allowance, Current
Total current assets
Assets, Current
Property, plant and equipment, net
Property, Plant and Equipment, Net
Deferred costs
Deferred Costs, Noncurrent
Goodwill
Goodwill
Other assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities and Equity [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses and other current liabilities
Accrued Liabilities, Current
Long-term debt, current maturities
Long-term Debt, Current Maturities
Total current liabilities
Liabilities, Current
Deferred revenue
Deferred Revenue, Noncurrent
Deferred income tax liability
Deferred Tax Liabilities, Net, Noncurrent
Other liabilities
Other Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise
Total liabilities
Liabilities
Stockholders' equity
Stockholders' Equity Attributable to Parent [Abstract]
Common stock ($.0001 par value, 100,000,000 shares authorized, 54,114,296 and 53,504,296 issued and outstanding at September 30, 2015, and December 31, 2014, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total stockholders' equity
Stockholders' Equity Attributable to Parent
Total liabilities and stockholders' equity
Liabilities and Equity
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Text Block]
The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
Administration of Chapter 11 Case [Abstract]
Administration of Chapter 11 Case [Abstract]
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event [Member]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Debt Satisfied
Debt Satisfied
The Company was authorized by the Bankruptcy Court to satifsy a fully-secured term loan.
Prepetition claim satisfied
Prepetition Claim Satisfied
The Company has satisfied a prepetition claim as part of the assumption of the Commercial Manufacturing Agreement, as amended, pursuant to orders of the Bankruptcy Court.
Rent reduction
Rent Reduction
The amount of reduced monthly rent for the research and development facility due to the addendum to the Commercial Lease.
Proof of claim, withdrawn
Proof of Claim, Withdrawn
Proof of claim from commercial lease for research facility, withdrawn.
Payment To Extend Days To Satisfy Claim
Payment To Extend Days To Satisfy Claim
Total amount of payment to PharmAthene to extend the number of days to satisfy the claim.
Amount To Be Paid On Effective Date of Plan Of Reorganization
Amount To Be Paid On Effective Date of Plan Of Reorganization
The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization.
Amount of unliquidated proof of claim
Bankruptcy claims, amount of unliquidated claim
The amount of unliquidated proof of claim filed with the Bankruptcy Court.
Proofs of claim, amount of claims filed
Bankruptcy Claims, Number Of Claims Outstanding
The aggregate number of claims outstanding with the bankruptcy court.
Amount of liquidated proofs of claims
Proof Of Claim Asserted In Connection With Litigation
Proof of claim asserted in connection with litigation field with the Bankruptcy Court.
Final Order And Judgment
Final Order And Judgment
Final order and judgment entered by the Court awarding damages to the Plaintiff.
Proof of claim asserted in connection with litigation
Bankruptcy claims, all other liquidated proof of claims
The total dollar value of all other liquidated proof of claims, outside of the litigation.
Liabilities Subject to Compromise, Cash Disbursements and Reclassification Increase (Decrease) under Bankruptcy Court Order, Resolutions of Contingencies Subject to Chapter 11
Liabilities Subject to Compromise, Cash Disbursements and Reclassification Increase (Decrease) under Bankruptcy Court Order, Resolutions of Contingencies Subject to Chapter 11
Bankruptcy Claims, Number of Claims Settled
Bankruptcy Claims, Number of Claims Settled
Bankruptcy Claims, Amount Paid to Settle Claims
Bankruptcy Claims, Amount Paid to Settle Claims
Statement of Cash Flows [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and other amortization
Depreciation, Depletion and Amortization
Increase (decrease) in fair value of warrants
Increase In Fair Value Of Warrants
Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.
Stock-based compensation
Share-based Compensation
Write-off of leasehold improvements
Gain (Loss) on Disposition of Property Plant Equipment
Gain on sale of assets
Gain (Loss) on Disposition of Assets
Non-cash interest expense
Other Noncash Expense
Changes in assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventory
Increase (Decrease) in Inventories
Deferred costs
Increase (Decrease) in Deferred Charges
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense
Other assets
Increase (Decrease) in Other Operating Assets
Deferred income taxes, net
Deferred Income Tax Expense (Benefit)
Accounts payable, accrued expenses and other current liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise, Period Increase (Decrease)
Deferred revenue
Increase (Decrease) in Deferred Revenue
Increase (Decrease) in Other Operating Liabilities
Increase (Decrease) in Other Operating Liabilities
Net cash provided by (used in) operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Capital expenditures
Payments to Acquire Property, Plant, and Equipment
Proceeds from sale of assets
Proceeds from Sale of Productive Assets
Restricted Cash
Payments for (Proceeds from) Other Investing Activities
Net cash (used in) provided by investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Net proceeds from exercise of warrants and options
Proceeds From Issuance Of Warrants and Options
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Payment of common stock tendered for employee tax obligations
Payments Related to Tax Withholding for Share-based Compensation
Repayments of long-term debt
Repayments of Long-term Debt
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Bonus
Accrued Bonuses, Current
Professional fees
Accrued Professional Fees, Current
Vacation
Accrued Vacation, Current
Taxes Payable
Taxes Payable
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
Other
Other Accrued Liabilities, Current
Total
Inventory Disclosure [Abstract]
Inventory
Inventory Disclosure [Text Block]
Liabilities Subject to Compromise [Abstract]
Liabilities subject to compromise
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
Affiliated Entity [Member]
Affiliated Entity [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
Service agreement term
Service Agreement Term 1
Service agreement, entered into with MacAndrews & Forbes LLC ("M&F"), in years.
Commitment to Invest
Commitment to Invest
Related party commitment to invest at the Company's discretion in exhange for common stock and warrants.
Warrants to purchase percentage of acquired shares
Warrants to Purchase Percentage of Shares
Related party commitment to invest at the Company's discretion in exhange for warrants to purchase a percentage of the number of Company shares acquired by the related party.
Warrants to purchase common stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Proceeds from issuance of warrants and options
Proceeds From Issuance Of Warrants and Options 1
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Exercise price of warrants to purchase common stock
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrants contractrual term
Warrants contractrual term
The contractual life of warrants.
Fair value adjustment of warrants
Expense of warrants held as assets
Expense of Warrants Held as Assets
The expense associated with warrants held as assets.
Property, Plant and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Table Text Block]
Tabular disclosure of the components of accrued liabilities and other current liabilities.
Inventory, Current [Table]
Inventory, Current [Table]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Domain]
Procurement Contract [Domain]
Procurement Contract [Domain]
BARDA Contract
Barda Contract [Member]
Barda Contract [Member]
Inventory [Line Items]
Inventory [Line Items]
Courses delivered provisional dosage, twice daily
Number of courses delivered and accepted
Number of tecovirimat, also known as ST-246, courses delivered and accepted to the U.S. Strategic National Stockpile.
Work in process
Inventory, Work in Process and Raw Materials
Finished goods
Inventory, Finished Goods, Net of Reserves
Inventory write-downs
Inventory Write-downs
Inventory write-downs included in research and development expense on the balance sheet.
Per Share Data
Earnings Per Share [Text Block]
Deferred revenue
Liabilities subject to compromise, deferred revenue
The amount of pre-petition deferred revenue included in liabilities subject to compromise.
Accounts payable - pre-petition
Liabilities subject to compromise, accounts payable
The amount of pre-petition trade accounts payable included in liabilities subject to compromise.
Expectation damages accrual- PharmAthene Litigation
Loss Contingency Accrual
Legal and expert fees accrual - PharmAthene Litigation
Liabilities subject to compromise, loss contingency legal fees
The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise.
Other accrued expenses - pre-petition
Liabilities subject to compromise, other accrued expense
The amount of pre-petition accrued expense included in liabilities subject to compromise.
Liabilities Subject to Compromise
Surety bond
Surety bond
Amount of surety bond.
Payment to post collateral for surety bond
Payment to Post Collateral for Surety Bond
Payment to post collateral for surety bond.
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Loss Contingencies [Table]
Loss Contingencies [Table]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case Type [Domain]
Litigation Case [Domain]
License Agreement litigation
License Agreement Litigation [Member]
License Agreement Litigation [Member]
Litigation Status [Axis]
Litigation Status [Axis]
Litigation Status [Domain]
Litigation Status [Domain]
Pending litigation
Pending Litigation [Member]
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Surety bond
Surety Bond [Member]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Accrued liabilities
Accrued Liabilities [Member]
Other assets
Other Assets [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Percentage of net profits from sales after net profit threshold
Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Net profit threshold
Net Profit Milestone
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale
Equitable payment stream following first commercial sale, duration
Duration of Equitable Payment Stream Following First Commercial Sale
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Percentage of litigation costs awarded
Litigation Costs Awarded, Percentage
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Plaintiff attorneys' fee and expenses
Amount Plaintiff May Recover
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Collateral
Collateral
Percentage of cash collateral for surety bond.
Litigation costs awarded, remand proceedings
Litigation Costs Awarded, Remand Proceedings
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expenses it incurred in the remand proceedings.
Litigation costs awarded, pretrial and trial phases
Litigation Costs Awarded, Pretrial and Trial Phases
The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in the pretrial and trial phases.
Litigation costs awarded, expert fees remand proceedings
Litigation Costs Awarded, Expert Fees Remand Proceedings
The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in remand proceedings.
Final order and judgment including interest
Final order and judgment plus interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Final order and judgment post-judgment interest
Final Order And Judgment Post-Judgment Interest
Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff.
Per Diem Interest
Per Diem Interest
Per Diem Interest on post judgment amount on the Final Order Judgment entered by the court awarding damages on the PharmAthene litigation
Loss contingency accrual
Liabilities subject to compromise, loss contingency legal fees
Final Order And Judgment Pre and Post-Judgment Interest
Final Order And Judgment Pre and Post-Judgment Interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre and post-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Document and Entity Information [Abstract]
Document and Entity Information [Abstract]
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Trading Symbol
Trading Symbol
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Capital Deficiency
Net Capital Deficiency
Net Capital Deficiency. Net capital is equal to the net worth of the broker dealer, less certain items such as exchange memberships, carrying value of securities not readily marketable, haircuts on marketable securities in proprietary accounts, furniture and equipment and other illiquid assets as defined.
Income Tax Disclosure [Abstract]
Current income tax expense (benefit)
Current Income Tax Expense (Benefit)
Income (loss) from continuing operations before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Term loan
Debt, Long-term and Short-term, Combined Amount
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Leasehold improvements, gross
Leasehold Improvements, Gross
Computer equipment, gross
Computer Equipment
The gross amount of capitalized computer equipment costs as of the balance sheet date.
Furniture and fixtures, gross
Furniture and Fixtures, Gross
Property, plant and equipment, gross
Property, Plant and Equipment, Gross
Accumulated depreciation, depletion and amortization, property, plant, and equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, plant and equipment, net
Depreciation and other amortization
Inventory [Abstract]
Inventory [Abstract]
Inventory
Schedule of Inventory, Current [Table Text Block]
Liabilies subject to compromise [Table Text Block]
Liabilies subject to compromise [Table Text Block]
[Table Text Block] for Schedule of liabilities that are subject to compromise.
Reorganization items [Table Text Block]
Reorganization items [Table Text Block]
The schedule represents a summary of reorganization items.
Schedule of antidilutive securities excluded from computation of earnings per share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Income Tax
Income Tax Disclosure [Text Block]
Procurement Contract [Table]
Procurement Contract [Table]
Procurement Contract [Table]
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Number of courses to be delivered
Number of Courses To Be Delivered 1
Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile
Value of contract
Government Contract, Value of Award 1
Value of base contract award.
Contract Value of Manufacturing and Delivery Activities
Contract Value of Manufacturing and Delivery Activities
Contract value of manufacturing and delivery activities.
Contract value of development and support activities
Contract Value of Development and Support Activities
Contract value of development and support activities
Contract value of various options
Contract Value of Various Options
Contract value of various options exercisable at BARDA's discretion.
Number of courses under modified contract
Government Contract, Number of Courses Purchased Under Modified Contract
Government contract, number of courses to be purchased under modified contract.
Number of courses contributed at no additional cost to the government
Government Contract, Number of Courses Manufactured Using Federal Funds
Government contract, number of courses to be delivered that were manufactured using federal funds under prior development contracts.
Proceeds from manufacture and physical delivery of courses, government contract
Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts
Proceeds from manufacture and physical delivery of courses, government contracts.
Proceeds from advance payments under the BARDA contract
Proceeds from Advance Payments, Government Contracts
Proceeds from advance payments, government contracts
Milestone payment
Milestone payment
Proceeds from milestone payment, Government contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds from physical delivery of courses, government contract.
Courses delivered
Government contract, number of free courses delivered and accepted
Government Contract, Number of Free Courses Delivered and Accepted
Number of courses of tecovirimat delivered and accepted to the Strategic Stockpile at no cost to the government.
Number of courses delivered and accepted at provisional dosage, once daily
Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily
Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile.
Procurement Contract Deferred Cost, Noncurrent
Procurement Contract Deferred Cost, Noncurrent
Sum of the carrying amounts of deferred costs, for only the procurement contract, that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.
Courses delivered provisional dosage, twice daily
Courses Delivered Provisional Dosage, Twice Daily
Courses of tecovirimat delivered to the Strategic Stockpile at the provisional dosage of 600 mg twice daily (1,200 mg per day).
Deferred revenue
Deferred Revenue, Additions
Research and development revenue long-term contract
Research and Development Revenue Long-term Contract
Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product.
Number of active contracts
Number of Active Contracts
Number of active contracts.
Number of active grants
Number of Active Grants
Number of active grants
Potential future research and development funding
Potential Future Aggregate Research and Development Expenses
Potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion.
Potential milestone payments
Potential milestone payments
Potential later stage milestone payments and royalties.
Potential royalties
Potential royalties
Maximum percentage of potential royalties on sales of drugs that use transferred intellectual property rights.
Potential percentage cash distributions
Potential percentage cash distributions
Potential percentage cash distributions of profit interest units.
Contract Value, Option, FDA Approval
Contract Value, Option, FDA Approval
Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.
Contract Value, Detail Of Option Exercisable, Development Activities
Contract Value, Detail Of Option Exercisable, Development Activities
Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.
Contract Value, Detail Of Option Exercisable, Production Activities
Contract Value, Detail Of Option Exercisable, Production Activities
Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.
Reorganizations [Abstract]
Administration of Chapter 11 Case [Text Block]
Administration Of Chapter 11 Case [Text Block]
The entire disclosure for the description of the administration of the Chapter 11 case under the US Bankruptcy Code.
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Member of Board of Directors
Management [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Free rent period
Free Rent Period
Free Rent Period in months allowed under the sublease.
Monthly rental payments first five years
Monthly Rental Payments First Five Years
The amount of the monthly rental payments due under the sublease entered into for the first five years.
Initial rent period
Initial Rent Period
Represents the number of years for the initial rent period of five years and related monthly payments.
Monthly rental payments after five years
Monthly Rental Payments After Five Years
The amount of the monthly rental payments due under the sublease entered into after the first five years.
Rent period after first five years
Rent Period After First Five Years
Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase.
Legal fees
Legal Fees
Accounts payable to related party
Accounts Payable, Related Parties
Related Party Transaction, Expenses from Transactions with Related Party
Related Party Transaction, Expenses from Transactions with Related Party
Organization, Consolidation and Presentation of Financial Statements Disclosure
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]